Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Professor Jeremiah Stamler (1919-2022), "Father of Preventive Cardiology".

Atherosclerosis·2022
Same author

[Are triglyceride rich lipoproteins more dangerous than LDL cholesterol?]

Lakartidningen·2021
Same author

[Prevention of cardiovascular disease needs longer-term perspective].

Lakartidningen·2020
Same author

Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease.

Diabetes care·2020
Same author

Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial.

American heart journal·2020
Same author

Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.

Journal of the American College of Cardiology·2019

Related Experiment Videos

Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL

Matti J Tikkanen1, Michael Szarek, Rana Fayyad

  • 1Department of Medicine, Division of Cardiology, Helsinki University Central Hospital, 00290 Helsinki, Finland. matti.j.tikkanen@helsinki.fi

Journal of the American College of Cardiology
|January 20, 2010
PubMed
Summary

High-dose atorvastatin significantly reduces recurrent cardiovascular events compared to usual-dose simvastatin. Intensive statin therapy is more effective beyond the first event for patients with multiple cardiovascular events.

Related Experiment Videos

Area of Science:

  • Cardiology
  • Clinical Trials
  • Pharmacology

Background:

  • Time-to-first-event analysis is common in cardiovascular trials but overlooks subsequent events.
  • Recurrent cardiovascular events significantly impact patient outcomes and trial data.

Purpose of the Study:

  • To compare the efficacy of high-dose atorvastatin versus usual-dose simvastatin in preventing recurrent cardiovascular events.
  • To analyze events beyond the first occurrence using the Wei, Lin, and Weissfeld method.

Main Methods:

  • Post-hoc analysis of the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) trial.
  • Application of the Wei, Lin, and Weissfeld method for analyzing recurrent events.
  • Utilized Cox proportional hazards model for marginal event distribution.

Main Results:

  • High-dose atorvastatin (80 mg) reduced the relative risk of a second cardiovascular event by 24% (p < 0.0001) compared to simvastatin (20-40 mg).
  • Significant risk reductions were observed for third (19%, p=0.035) and fourth (24%, p=0.058) events with atorvastatin.
  • Atorvastatin demonstrated a trend towards greater efficacy in preventing subsequent events, including the fifth event (28%, p=0.117).

Conclusions:

  • Intensive statin therapy with high-dose atorvastatin is more effective than standard therapy in preventing recurrent cardiovascular events.
  • Clinicians should consider high-dose statins for patients experiencing multiple cardiovascular events.
  • The findings support aggressive lipid-lowering strategies for long-term cardiovascular event prevention.